Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12747MR)

This product GTTS-WQ12747MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ12747MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3162MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ2592MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ8196MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ11676MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ3282MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ11793MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ14594MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SAR-650984
GTTS-WQ14349MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG7716
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW